Dieta enriquecida com rosiglitazona não protege a lesão de isquemia e reperfusão hepática em modelo experimental no rato by TEIXEIRA, Antonio Roberto Franchi et al.
378  -    Acta Cirúrgica Brasileira - Vol. 23 (4) 2008
13 - ORIGINAL ARTICLE
Ischemia-Reperfusion
Rosiglitazone-enriched diet did not protect liver ischemia-reperfusion injury in a rat
model1
Dieta enriquecida com rosiglitazona não protege a lesão de isquemia e reperfusão hepática
em modelo experimental no rato
Antonio Roberto Franchi TeixeiraI, Nilza Trindade MolanII, Marta Bellodi-PrivatoIII, Ana Maria CoelhoII, Kátia Ramos
LeiteIV, Antônio Carlos SeguroV, Telésforo BacchellaVI, Marcel Cerqueira César MachadoVII
I Assistant Surgeon, Transplantation Division, Department of Gastroenterology, School of Medicine, USP, Brazil.
II Pharmacist, Transplantation Division, Department of Gastroenterology, School of Medicine, USP, São Paulo, Brazil.
III Post-Doctor Student, Transplantation Division, Department of Gastroenterology, School of Medicine, USP, São Paulo, Brazil.
IV Assistant Pathologist, Department of Urology, School of Medicine, USP, São Paulo, Brazil.
V Associate Professor, Department of Nephrology, School of Medicine, USP, São Paulo, Brazil.
VI Associate Professor, Surgeon-in-Chief, Transplantation Division, Department of Gastroenterology, School of Medicine, USP, São Paulo,
Brazil.
VII Former Chairman, Transplantation Division, Department of Gastroenterology, School of Medicine, USP, São Paulo, Brazil.
ABSTRACT
Purpose: To determine whether rosiglitazone-enriched diet offer protection in a classical model of liver ischemia-reperfusion
injury in rats. Methods: Two days before the experiment, rats were divided into 2 groups: Control Group (n=13) rats fed with
standard diet; Rosi Group (n=13): rats fed with a powdered standard diet supplemented with rosiglitazone. The animals were
submitted to liver ischemia-reperfusion by clamping the pedicle of median and left anterolateral lobes. After 1 hour of partial
hepatic ischemia, the clamp was removed for reperfusion. After 2 or 24 hours (Control and Rosi Groups), blood was collected for
enzymes and cytokines analysis. Ischemic and non-ischemic liver were collected for malondialdehyde analysis and histological
assessment. Lungs were removed for tissue myeloperoxidase quantification. Results: There were no statistical differences be-
tween groups for all analysed parameters. Conclusion: In this model, rosiglitazone-enriched diet did not protect liver against
ischemia-reperfusion injury.
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RESUMO
Objetivo: Determinar se a dieta enriquecida com rosiglitazona oferece proteção em um modelo clássico de lesão de isquemia e
reperfusão hepática em ratos. Métodos: Dois dias antes do experimento, os ratos foram divididos em 2 grupos: Grupo Controle
(n=13): ratos alimentados com dieta padrão; Grupo Rosi (n=13): ratos alimentados com dieta em pó padrão enriquecida com
rosiglitazona. Os animais foram submetidos à isquemia e reperfusão hepática por clampeamento do pedículo dos lobos médio e
anterolateral esquerdo. Após 1 hora de isquemia, o clampe foi removido para a reperfusão. Após 2 ou 24 horas (Grupos Controle
e Rosi), o sangue foi coletado para análise de enzimas e citocinas. Os fígados isquêmico e não isquêmico foram coletados para
análise de malondialdeído e avaliação histológica. Pulmões foram removidos para quantificação da mieloperoxidase tecidual.
Resultados: Não houve diferenças estatísticas entre grupos em todos os parâmetros analisados. Conclusão: Nesse modelo, a
dieta enriquecida com rosiglitazona não protegeu contra a lesão de isquemia e reperfusão hepática.
Descritores: Isquemia. Reperfusão. Fígado. Ratos.
1 Research performed of Transplantation Division, Laboratory of Medical Investigation #LIM37, Department of Gastroenterology, School of
Medicine, University of São Paulo (USP), Brazil.
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Introduction
Liver ischemia-reperfusion injury (LIRI) is a phenom-
enon inevitable after hepatic surgery, liver transplantation, shock
and trauma1. Hepatic ischemia-reperfusion leads to an acute in-
flammatory response, causing significant hepatocellular dam-
age and organ dysfunction. Mechanisms of LIRI involve com-
plex and multiple pathways, including the direct ischemic cel-
lular damage as well as the cell injury due to the activation of
inflammatory response after reperfusion2. The accumulation of
inflammatory cells contributes to the progression of parenchy-
mal injury. Despite the recent improvements in liver preserva-
tion and surgical techniques, LIRI remains an important clini-
cal complication.
An important pathway involved in inflamation and re-
generation is the peroxisome proliferator-activated receptors
(PPARs) family. PPARs are members of the nuclear hormone
receptor superfamily of ligand-dependent transcription factors3.
The PPAR subfamily comprises three members, PPAR-α,
PPAR-ȕ , and PPAR-Ȗ4. Thiazolidinediones (pioglitazone,
troglitazone, and rosiglitazone) are synthetic PPAR-Ȗ agonists
and they act to enhance insulin sensitivity and reduce serum
glucose in diabetic patients5. Therefore, they are now widely
used as antidiabetic agents. Besides the antidiabetic activity, it
has been recently recognized to have other various physiologi-
cal roles including inflammation. In particular, PPAR-Ȗ may be
a protective regulator against ischemic damage. In the liver, it
has been suggested that PPAR-Ȗ agonists are protective against
liver injury in chronic disease conditions such as cirrhosis and
fibrosis6. A recent study showed that PPAR-Ȗ plays an inhibi-
tory role in LIRI and the stimulation by selective agonist has a
significant beneficial effect in mice. This protective effect of
pioglitazone was associated with downregulation of the local
expression of several potent proinflammatory cytokines,
chemokines and adhesion molecules after reperfusion7. One
speculate if PPAR-Ȗ agonists may have a therapeutic role in
liver ischemia-reperfusion injury.
Our aim was to determine whether rosiglitazone-en-
riched diet could offer protection in a classical model of liver
ischemia-reperfusion injury in rats.
Methods
The study was designed in accordance with the Guide
for the Care and Use of Laboratory Animals published by the
US National Institutes of Health and the Guidelines of Animal
Experimentation of the University of São Paulo School of Medi-
cine, São Paulo, SP, Brazil, for the care and use of laboratory
animals. Male Wistar rats weighing 250 ± 5 g were housed in a
room with a temperature of 23 ± 1ºC and a controlled 12-h
light/dark cycle. Animals were anestethized with ketamin 5%
(30 mg/kg) and xylazine 2% (30 mg/kg) intraperitonially. Dur-
ing the experiment, animals were warmed by a halogen light
(45W, 127V) and corporeal temperature was monitorized by a
rectal digital thermometer (YSI Precision 4000A thermometer,
USA) and kept around 37°C. Animals were allowed to sponta-
neous ventilation with an oxygen-enriched mixture (40%) dur-
ing all the procedure.
The experimental protocol was pre-approved by Eth-
ics Commission of the Hospital das Clínicas , University of São
Paulo, Brazil.
Twenty six male Wistar rats, provided by the Medical
Investigation Laboratory #37 (LIM-37) were used. Two days
before the experiment, rats were divided into 2 groups: Control
Group (n = 13): rats fed with standard diet; Rosi Group (n = 13):
rats fed with a powdered standard diet supplemented with
rosiglitazone to produce mixture with 92 mg/kg. All animals
were allowed to have free access to diet and water. The food
intake in milligrams was monitored daily (2.8 mg/rat/day).
Animals were than submitted to liver ischemia-
reperfusion procedure. Briefly, a median laparotomy was per-
formed and the pedicle of median and left anterolateral seg-
ments was dissected, exposed and clamped with an atraumatic
microvascular bulldog clamp. In this technique, pedicle clamp-
ing is completely reversible, avoiding intestinal and caval sta-
sis. After clamping, the abdominal wall was closed with
ininterrupted 4-0 nylon suture in order to avoid dehydration.
After 1 hour of partial hepatic ischemia, the clamp was removed
to initiate hepatic reperfusion.
After 2 or 24 hours (Control and Rosi Groups), the
animals were anestethized again and 5 ml of blood was col-
lected by cardiac punction for biochemical analysis. Rats were
than killed by aorta section. The liver was collected and identi-
fied as “ischemic liver” and “non-ischemic liver” for
malondialdehyde analysis. For histological assessment liver was
collected 24 hours after reperfusion.
Pulmonary artery was catheterized via right
ventriculum with a plastic 2,0 mm diameter tube (Silastic, Dow
Corning, no. 602.175) and 40 ml of saline 0.9% was infused, at
a rate of 10ml/min. Lungs were removed for tissue
myeloperoxidase quantification.
Liver enzymes
Hepatic enzymes [alanine aminotransferase (ALAT),
aspartate aminotransferase (ASAT), alkaline phosphatasis (AP)
and gamma-glutamyltransferase (GGT)] levels were quantified
using a clinical chemistry kit (Testline – SG Tecnologia Clínica,
São Paulo, Brazil) on Cobas Mira analyzer, according to the
manufacturer’s instructions.
TNF-α and interleukines
Serum TNF-α, IL-6 and IL-10 concentrations were
measured in duplicate using a commercially available enzyme-
linked immunosorbent assay kit (Biosource International
Cytoscreen, Camarillo, CA) according to the manufacturer’s
instructions. The concentrations were expressed in pg/ml.
Pulmonary myeloperoxidase
Pulmonary myeloperoxidase (MPO) activity was used
as an indicator of neutrophil accumulation. Samples of lung
tissue homogenized with a Polytron® homogenizer using a buffer
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that contains 0.5% hexadecyltrimethyl ammonium bromide,
5mmol/L EDTA, and 50 mmol/L phosphate at pH 6.0. Homog-
enized samples were sonicated and centrifugated (3000g, 30
minutes) at 40C. MPO activity in the supernatant was assayed
by measuring the change in A460 resulting from the decomposi-
tion of H2O2 in the presence O – dianiside. Results are expressed
as optimal density (OD) at 490 nm.
Malondialdehyde measurement
Malondialdehyde (MDA) levels in the samples were
determined to obtain quantitative estimation of the membrane
lipid oxidative damage. MDA was assayed in terms of
thiobarbituric acid reactive substrats. The thiobarbituric acid
method was used to quantify lipid peroxidation in liver, mea-
sured as thiobarbituric acid-reactive substances (TBARS). Liver
tissues (100 mg/mL) were homogeneized in 1.15% KCl buffer,
and centrifuged at 14,000 g for 20 min. The supernatant was
then stores at -70°C. an aliquot of the supernatant was added to
a reaction mixture of 1.5 mL 0.8% thiobarbituric acid, 200 µL
8.1% (v/v) SDS, 1.5 mL 20% (v/v) acetic acid, pH 3.5, and 300 µL
distilled H2O, and heated to 90°C for 45 min. After cooling to
room temperature, the samples were cleared by centrifugation
at 10,000 g for 10 min, and their absorbance was measured at
532 nm using malondialdehyde bis (dimethyl acetal) as an ex-
ternal standard. The quantity of lipid peroxides is reported in
nmol malondialdehyde (MDA) equivalents/mg protein.
Histological analysis
Fragments of liver tissue previously fixed in 10% for-
malin solution were processed and stained with hematoxylin-
eosin. The following histological variables were assessed: pa-
renchymal detrabeculation, presence of apoptosis, cellular
edema and congestion.
Statistical analysis
Comparisons between groups were statistically ana-
lyzed using a GraphPad Prism 2.01 software (San Diego, CA,
USA). A nonparametric test (Mann-Whitney) was performed
since the data distribution was considered as non-Gaussian.
Mean values and SEM were displayed in graphics only as addi-
tional information. Differences were considered statistically
significant when p < 0.05.
Results
There were no statistical differences between Control
Group and Rosi Group concerning liver enzymes after two and
twenty-four hours of reperfusion (Figures 1-4).
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FIGURE 1 - Serum levels of aspartate aminotransferase (ALT) after
two hours (A: Control Group: 2484±438.4, Rosi Group: 2301±527.5)
and twenty-four hours (B: Control Group: 453.3±131.3, Rosi Group:
888.3±245.1) of reperfusion
ALT
FIGURE 2 - Serum levels of alanine aminotransferase after two hours
(A: Control Group: 2197±247.4, Rosi Group: 2044±384.7) and twenty-
four hours (B: Control Group: 320.0±102.7, Rosi Group: 591.7±190.3)
of reperfusion
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GGT
FIGURE 3 - Serum levels of gamma-glutamyltransferase. (GGT) af-
ter two hours (A: Control Group: 5.00±0.62, Rosi Group: 5.67±0.80)
and twenty-four hours (B: Control Group: 5.16±0.91, Rosi Group:
5.83±0.83) of reperfusion
AP
FIGURE 4 - Serum levels of alkaline phosphatasis (AP) after two
hours (A: Control Group: 866.0±69.81, Rosi Group: 839.0±29.67) and
twenty-four hours (B: Control Group: 617.8±61.6, Rosi Group:
668.5±45.1) of reperfusion
FIGURE 5 - Serum levels of tumor necrosis alpha (TNF-α) (Control Group: 87.0±43.64, Rosi Group: 53.33±27.75), interleukin-6 (IL-6)
(Control Group: 106.5±37.11, Rosi Group: 88.0±22.55), interleukin-10 (IL-10) (Control Group: 98.86±24.05, Rosi Group: 81.83±26.33) two
hours of reperfusion
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The cytokines TNF-α, IL-6, IL-10 were assessed only
after two hours of reperfusion and differences between Control
and Rosi Groups were not significant as well (Figure 5).
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Pulmonary MPO (Figure 6) and hepatic MDA - in the
ischemic (Figure 7) and non-ischemic liver (Figure 8) - were
also analyzed after two and twenty-four hours of reperfusion in
Control and Rosi Groups. Differences between the groups were
not observed.
FIGURE 6 - Pulmonary myeloperoxidase (MPO) activity after two
hours (A: Control Group: 0.173±0.02, Rosi Group: 0.154±0.011) and
twenty-four hours (B: Control Group: 0.1065±0.019, Rosi Group:
0.0676±0.013) of reperfusion
Ischemic Liver
Non Ischemic Liver
FIGURE 7 - Thiobarbituric acid-reactive substances-malondialdehyde
(MDA) equivalents in ischemic liver samples after two hours (A: Con-
trol Group: 3.6±0.53, Rosi Group: 2.87±0.43) and twenty-four hours
(B: Control Group: 3.84±1.08, Rosi Group: 2.16±0.36) of reperfusion
FIGURE 8 - Thiobarbituric acid-reactive substances-malondialdehyde
(MDA) equivalents in non ischemic liver samples after two hours (A:
Control Group: 3.21±0.52, Rosi Group: 2.99±0.42) and twenty-four
hours (B: Control Group: 2.05±0.22, Rosi Group: 1.60±0.36) of
reperfusion. C: Comparison between A and B only for Rosi Group (2
hours: 2.99±0.42, 24 hours: 1.60±0.36)
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Histological assessment of ischemic and non-ischemic
lobes (only after 24 hours of reperfusion) was performed by an
experienced pathologist and showed a menagerie of mild alter-
ations (detrabeculation, apoptotic bodies, congestion) not dif-
ferent between the groups (photographies not shown).
Discussion
Pro-inflammatory cytokines are up-regulated during
acute liver injury. The increment of TNF-α and IL-6 has been
associated with ischemic damage and lack of tissue protection8.
They are responsible for the induction of neutrophil sequestra-
tion in the lungs9, analyzed by lung leukocyte recruitment
(MPO). On the other hand, IL-10 appears to have an attenuat-
ing effect on organ damage, due to its anti-inflammatory prop-
erties10.
There are some evidences that PPAR-Ȗ agonists may
suppress the production of IL-1, IL-6 and TNF-α in stimulated
human peripheral blood monocytes11.
The potential protective effect of thiazolidinediones
in LIRI are under investigation. These drugs might have a role
in clinical situations such as hepatectomies and liver transplan-
tation. Theoretically, a patient could receive rosi or pioglitazone
prior to a liver resection when ischemia is planned. Similarly, a
liver donor could receive these drugs in intensive care unit be-
fore multiorgan retrieval, in order to protect tissues from is-
chemia reperfusion injury.
In this study, we tested the effects of a rosiglitazone-
enriched diet in a classical model of LIRI in rats, focusing in
the early (2hs) and delayed (24hs) effects of the drug.
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We assessed classical markers of liver injury (AST,
ALT, AP, GGT), pro- and anti-inflammatory cytokines (IL-6,
TNF-α and IL-10) and lung leukocyte recruitment (MPO). We
also evaluated lipid peroxidation (MDA) and liver histology in
ischemic and non-ischemic liver in both groups.
Analyzing our results, we found that liver enzymes
peaks (ALT, AST, AP and GGT) reached values that confirm
clamping promoted effective hepatocyte injury. Statistical dif-
ferences between Control and Rosi groups were not signifi-
cant. It means that rosiglitazone did not modify the degree of
injury inflicted to the hepatocytes.
Similarly, TNF-α, IL-6, IL-10 and lung myeloperoxidase (MPO)
was not modulated by rosiglitazone administration.
Nevertheless, others researchers found beneficial ef-
fects of thiazolidinediones administration in a different model
of LIRI in mice. Kuboki et al. demonstrated that PPAR-Ȗ acti-
vation by rosiglitazone offers protection against hepatic ischemia
(90 minutes) followed by eight hours of reperfusion. They
showed that PPAR-Ȗ is constitutively activated in normal liver
and that hepatic ischemia causes a rapid decrease in PPAR-Ȗ
DNA binding. They suggest that PPAR-Ȗ is an important en-
dogenous regulator of, and potential therapeutic target for, is-
chemic liver injury12. The differences between our and Kuboki’s
results may relay on the fact they applied a longer period of
ischemia.
Lipid peroxidation refers to the oxidative degradation
of lipids. It is the process where free radicals transfer electrons
from the lipids to cell membranes, resulting in cell damage.
The main final product of this reaction is malondialdehyde
(MDA) and it is reactive with thiobarbituric acid (TBARS)13.
To our knowledge, this is the first time that the potential capac-
ity of rosiglitazone to ameliorate lipid peroxidation induced by
LIRI was tested in an animal model. Our results did not show a
significant difference between Rosi and Control groups con-
cerning MDA analysis.
Despite these preliminary negative results, there are
evidences that thiazolidinediones may have an important role
in LIRI and further studies will be addressed in this direction.
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